AU2018365800A1 - Compositions and methods for treating cancer using RHOA dominant negative forms - Google Patents

Compositions and methods for treating cancer using RHOA dominant negative forms Download PDF

Info

Publication number
AU2018365800A1
AU2018365800A1 AU2018365800A AU2018365800A AU2018365800A1 AU 2018365800 A1 AU2018365800 A1 AU 2018365800A1 AU 2018365800 A AU2018365800 A AU 2018365800A AU 2018365800 A AU2018365800 A AU 2018365800A AU 2018365800 A1 AU2018365800 A1 AU 2018365800A1
Authority
AU
Australia
Prior art keywords
cancer
rhoa
cell
dominant negative
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018365800A
Other languages
English (en)
Inventor
Adam Bass
Haisheng Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2018365800A1 publication Critical patent/AU2018365800A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
    • C12Y306/05002—Small monomeric GTPase (3.6.5.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018365800A 2017-11-08 2018-11-05 Compositions and methods for treating cancer using RHOA dominant negative forms Abandoned AU2018365800A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762583166P 2017-11-08 2017-11-08
US62/583,166 2017-11-08
PCT/US2018/059188 WO2019094326A1 (en) 2017-11-08 2018-11-05 Compositions and methods for treating cancer using rhoa dominant negative forms

Publications (1)

Publication Number Publication Date
AU2018365800A1 true AU2018365800A1 (en) 2020-04-02

Family

ID=66439269

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018365800A Abandoned AU2018365800A1 (en) 2017-11-08 2018-11-05 Compositions and methods for treating cancer using RHOA dominant negative forms

Country Status (7)

Country Link
US (1) US11957739B2 (https=)
EP (1) EP3706751A4 (https=)
JP (1) JP2021502329A (https=)
CN (1) CN111278443A (https=)
AU (1) AU2018365800A1 (https=)
CA (1) CA3076269A1 (https=)
WO (1) WO2019094326A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11957739B2 (en) 2017-11-08 2024-04-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer using RHOA dominant negative forms
SE2000055A1 (sv) * 2020-03-15 2021-09-16 Martin Ivanov Denev Användande av fotohydrauliskt mekanisk chock, för selektiv sprängning av relativ svagare cellmembranen av cancerceller, vilka har svagare cellmembran än friska celler
CN113278706B (zh) * 2021-07-23 2021-11-12 广州燃石医学检验所有限公司 一种用于区分体细胞突变和种系突变的方法
WO2024059823A1 (en) * 2022-09-15 2024-03-21 Iview Therapeutics, Inc. Self-complementary AAV vectors carrying dominant negative RhoA and methods of use to treat ocular diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1274463A2 (en) * 1999-12-10 2003-01-15 Whitehead Institute For Biomedical Research Metastasis genes and uses thereof
WO2003030836A2 (en) * 2001-10-12 2003-04-17 Case Western Reserve University Neuronal regeneration
WO2005072141A2 (en) * 2004-01-16 2005-08-11 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of rhoa signaling
US7951924B2 (en) 2004-11-12 2011-05-31 University Of South Florida RhoB variants and methods of use
US7507534B2 (en) 2005-09-01 2009-03-24 National Health Research Institutes Rapid efficacy assessment method for lung cancer therapy
US20070161060A1 (en) 2005-09-07 2007-07-12 Anderson Richard A Screening method for identifying an agent that modulates PIPKIgamma trafficking of E-cadherin
ES2623447T3 (es) 2007-12-19 2017-07-11 Rhovac Aps Inmunoterapia basada en RhoC
WO2009089040A1 (en) * 2008-01-11 2009-07-16 Jaffrey Samie R Methods for expressing proteins in axons
EP2274617A4 (en) * 2008-04-10 2011-11-09 Massachusetts Inst Technology METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS
BR112013026199A2 (pt) * 2011-04-15 2017-11-07 Compugen Ltd polipeptídeo isolado, proteína de fusão, sequência de ácidos nucleicos, vetor de expressão ou um vírus, célula recombinante, método de produção de um polipeptídeo com ectodomínio solúvel lsr, ou seu fragmento ou proteína de fusão, composição farmacêutica, uso de um anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, uso do anticorpo ou do fragmento de ligação ao antígeno, uso de qualquer um de um polipeptídeo isolado, método de regulação por cima de citocinas, indução da expansão de células t, promoção da imunidade de células t específica antigênica e promoção da ativação das células t cd4+ e/ou cd8+ em um sujeito, método para potenciação de uma resposta imune secundária a um antígeno em um paciente, método de uso de pelo menos um de: um polipeptídeo isolado, método para tratamento ou prevenção de uma condição relacionada com o sistema imune, método para tratamento ou prevenção de uma doença infecciosa, método para diagnóstico de uma doença em um sujeito, método de produção de um polipeptídeo com ectodomínio solúvel tmem25, vsig10, ly6g6f, ou seu fragmento ou proteína de fusão, anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, método de imunoterapia em um paciente e método para combinação de vacinação terapêutica com um antígeno em conjunto com a administração de qualquer um de um polipeptídeo
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
US11957739B2 (en) 2017-11-08 2024-04-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer using RHOA dominant negative forms

Also Published As

Publication number Publication date
US11957739B2 (en) 2024-04-16
EP3706751A1 (en) 2020-09-16
CN111278443A (zh) 2020-06-12
US20200261550A1 (en) 2020-08-20
JP2021502329A (ja) 2021-01-28
CA3076269A1 (en) 2019-05-16
EP3706751A4 (en) 2021-08-18
WO2019094326A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
US20200206344A1 (en) Methods for modulating the interaction between ews-fli1 and baf complexes
CN109689062B (zh) 使用抗PI3Kβ和抗免疫检查点药剂的组合治疗PTEN缺陷型上皮癌的方法
AU2016229238B2 (en) PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers
EP3229837B1 (en) Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
AU2015328411C1 (en) Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
US11957739B2 (en) Compositions and methods for treating cancer using RHOA dominant negative forms
CN111148518A (zh) 使用cdk4/6抑制剂调控调节性t细胞和免疫应答的方法
EP3094736A2 (en) Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
WO2018148378A1 (en) Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy
US20200149042A1 (en) Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy
EP3215845A1 (en) Anti-galectin antibody biomarkers predictive of anti-immune checkpoint and anti-angiogenesis responses
US11852631B2 (en) Biomarkers predictive of anti-immune checkpoint response
US20220288051A1 (en) Methods for treating cancer using serial administration of e3 ubiquitin ligase degraders
US11366100B2 (en) P13K-MTORC1-S6K1 signaling pathway biomarkers predictive of anti-cancer responses
US20210032334A1 (en) Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
US20220289854A1 (en) Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
US20180223288A1 (en) Compositions and methods for the modulation of dna damage responses using bal1 and bbap
CA2977532C (en) Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers
HK40006303B (en) Methods for treating pten deficient epithelial cancers using a combination of anti-pi3kbeta and anti-immune checkpoint agents
HK40006303A (en) Methods for treating pten deficient epithelial cancers using a combination of anti-pi3kbeta and anti-immune checkpoint agents

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period